Drug Search Results
More Filters [+]

Zolunicant

Alternative Names: Zolunicant, mm-110, mm110
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

MM-110 has a novel Mechanism to Address a Critical Gap in OUD Treatment. (Sourced from: https://mindmed.co/programs-research/#scroll_section-2)

Mechanisms of Action: nAChR Antagonist

Novel Mechanism: No

Modality: N/A

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mind Medicine
Company Location: VANCOUVER A1 V6E 3Z3
Company CEO: Robert Barrow
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zolunicant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Opioid-Related Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events